MCE - Delayed Quote EUR

Grifols, S.A. (GRF.MC)

8.39 +0.30 (+3.71%)
At close: April 26 at 5:35 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,591,977.00
6,591,977.00
6,063,967.00
4,933,118.00
5,340,038.00
Cost of Revenue
4,097,406.00
4,097,406.00
3,832,437.00
2,970,522.00
3,084,873.00
Gross Profit
2,494,571.00
2,494,571.00
2,231,530.00
1,962,596.00
2,255,165.00
Operating Expense
1,758,913.00
1,758,913.00
1,529,328.00
1,400,087.00
1,279,832.00
Operating Income
735,658.00
735,658.00
702,202.00
562,509.00
975,333.00
Net Non Operating Interest Income Expense
-534,538.00
-534,538.00
-444,464.00
-256,151.00
-241,618.00
Other Income Expense
22,898.00
22,898.00
103,519.00
44,095.00
144,914.00
Pretax Income
224,018.00
224,018.00
361,257.00
350,453.00
878,629.00
Tax Provision
43,349.00
43,349.00
90,111.00
85,126.00
169,639.00
Net Income Common Stockholders
59,315.00
59,315.00
208,279.00
188,726.00
618,546.00
Diluted NI Available to Com Stockholders
59,315.00
59,315.00
208,279.00
188,726.00
618,546.00
Basic EPS
0.09
--
0.31
0.28
0.90
Diluted EPS
0.09
--
0.31
0.28
0.90
Basic Average Shares
679,756.29
--
679,805.14
681,556.94
685,515.74
Diluted Average Shares
679,756.29
--
679,805.14
681,556.94
685,515.74
Total Operating Income as Reported
799,398.00
799,398.00
805,680.00
595,064.00
996,132.00
Total Expenses
5,856,319.00
5,856,319.00
5,361,765.00
4,370,609.00
4,364,705.00
Net Income from Continuing & Discontinued Operation
59,315.00
59,315.00
208,279.00
188,726.00
618,546.00
Normalized Income
91,490.52
91,490.52
207,135.23
205,113.54
566,939.16
Interest Income
62,326.00
62,326.00
33,859.00
11,551.00
8,021.00
Interest Expense
516,060.00
516,060.00
444,543.00
233,813.00
222,921.00
Net Interest Income
-534,538.00
-534,538.00
-444,464.00
-256,151.00
-241,618.00
EBIT
740,078.00
740,078.00
805,800.00
584,266.00
1,101,550.00
EBITDA
1,181,996.00
1,181,996.00
1,213,664.00
944,033.00
1,423,083.00
Reconciled Cost of Revenue
3,762,627.00
3,762,627.00
3,512,630.00
2,703,535.00
3,084,873.00
Reconciled Depreciation
441,918.00
441,918.00
407,864.00
359,767.00
321,533.00
Net Income from Continuing Operation Net Minority Interest
59,315.00
59,315.00
208,279.00
188,726.00
618,546.00
Total Unusual Items Excluding Goodwill
-39,920.00
-39,920.00
1,523.00
-21,648.00
63,949.00
Total Unusual Items
-39,920.00
-39,920.00
1,523.00
-21,648.00
63,949.00
Normalized EBITDA
1,221,916.00
1,221,916.00
1,212,141.00
965,681.00
1,359,134.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-7,744.48
-7,744.48
379.23
-5,260.46
12,342.16
12/31/2020 - 5/17/2006

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BAYN.DE Bayer Aktiengesellschaft
27.40
+1.88%
 
SAN.PA Sanofi
91.23
-0.43%
 
NOVN.SW Novartis AG
89.50
-0.56%
 
ROG.SW Roche Holding AG
221.00
+1.01%
 
AZN.L AstraZeneca PLC
11,988.00
-0.32%
 
BAYRY Bayer Aktiengesellschaft
7.39
+1.65%
 
GSK.L GSK plc
1,653.00
+0.76%
 
RO.SW Roche Holding AG
240.00
+1.35%
 
REC.MI Recordati Industria Chimica e Farmaceutica S.p.A.
49.10
+0.61%
 
RHHBY Roche Holding AG
30.25
+0.77%